Meyka Pro banner
Synlab AG

Synlab AG (XETRA: SYAB.DE) Stock Competitors & Peer Comparison

See SYAB.DE's competitors and their performance on the XETRA and across the wider stock market.

SYAB.DE●XETRA
HealthcareMedical - Diagnostics & Research
€11.06
€0.02(0.18%)
German Market opens in 43h 27m

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for SYAB.DE and its XETRA peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
SYAB.DE€11.06-0.18%2.4B27.65€0.40+2.98%
TN8.DE€597.40-2.19%220.9B33.36€17.91+0.27%
DAP.DE€202.80-2.87%142.6B36.63€5.54+0.66%
ILU.DE€124.28+0.60%18.8B29.38€4.23N/A
QIA.DE€45.05+0.26%9.3B22.01€2.05+5.36%
MYD.DE€26.72+0.00%2.2B-256.92-€0.10N/A
NN6.DE€1.60-2.74%22.2M-10.67-€0.15N/A
ECX.DE€0.70-11.17%612.6K-0.04-€19.55N/A

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Thermo Fisher Scientific Inc. (XETRA: TN8.DE)

SYAB.DE vs TN8.DE Comparison October 2026

Synlab AG (XETRA: SYAB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SYAB.DE stands at 2.4B. In comparison, TN8.DE has a market cap of 220.9B. Regarding current trading prices, SYAB.DE is priced at €11.06 on the XETRA, while TN8.DE trades at €597.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SYAB.DE currently has a P/E ratio of 27.65, whereas TN8.DE's P/E ratio is 33.36. In terms of profitability, SYAB.DE's ROE is +0.11%, compared to TN8.DE's ROE of +0.13%. Regarding short-term risk, SYAB.DE is less volatile compared to TN8.DE. This indicates lower risk in terms of short-term price fluctuations for SYAB.DE.Check TN8.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions